| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| KRYSKrystal Biotech, Inc. | 8.18B | 282.01 | 94.00 | 473.02% | 53.3% | 17.48% | 1.46% | 0.01 |
| BMRNBioMarin Pharmaceutical Inc. | 10.58B | 55.07 | 24.92 | 17.97% | 16.82% | 8.59% | 4.49% | 0.11 |
| SRPTSarepta Therapeutics, Inc. | 2.23B | 21.31 | 9.11 | 52.97% | -11.25% | -20.57% | 0.88 | |
| RAREUltragenyx Pharmaceutical Inc. | 2.27B | 23.50 | -3.74 | 29.01% | -91.95% | -35.88% | 0.15 | |
| DYNDyne Therapeutics, Inc. | 2.7B | 16.42 | -4.87 | -61.26% | 0.04 | |||
| TVTXTravere Therapeutics, Inc. | 2.54B | 28.40 | -6.96 | 60.55% | -20.32% | -120.36% | 6.80 | |
| BEAMBeam Therapeutics Inc. | 3.25B | 32.05 | -7.00 | -83.18% | -7.44% | -42.92% | 0.22 | |
| SLNOSoleno Therapeutics, Inc. | 2.25B | 41.95 | -9.58 | -79.5% | -15.85% | 0.22 |
| Jun 2016 | Jun 2017 | Jun 2018 | Jun 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 346.51K | 450.31K | 455.45K | 11.32M | 97K | 59K | 73K | 75K | 0 | 0 |
| Revenue Growth % | -0.58% | 0.3% | 0.01% | 23.85% | -0.99% | -0.39% | 0.24% | 0.03% | -1% | - |
| Cost of Goods Sold | 103.8K | 209.02K | 331.3K | 426.51K | -185K | 123K | 9K | 381K | 343K | 396K |
| COGS % of Revenue | 0.3% | 0.46% | 0.73% | 0.04% | -1.91% | 2.08% | 0.12% | 5.08% | - | - |
| Gross Profit | 242.7K | 241.29K | 124.15K | 10.89M | 282K | -64K | 64K | -306K | -343K | -396K |
| Gross Margin % | 0.7% | 0.54% | 0.27% | 0.96% | 2.91% | -1.08% | 0.88% | -4.08% | - | - |
| Gross Profit Growth % | -0.7% | -0.01% | -0.49% | 86.72% | -0.97% | -1.23% | 2% | -5.78% | -0.12% | -0.15% |
| Operating Expenses | 16.2M | 4.4M | 8.68M | 8.99M | 8.56M | 13.53M | 17.92M | 18.77M | 22.25M | 41.37M |
| OpEx % of Revenue | 46.76% | 9.78% | 19.05% | 0.79% | 88.28% | 229.36% | 245.45% | 250.33% | - | - |
| Selling, General & Admin | 8.96M | 6.99M | 6.41M | 6.66M | 5.57M | 6.51M | 6.65M | 6M | 6.65M | 23.43M |
| SG&A % of Revenue | 25.86% | 15.52% | 14.07% | 0.59% | 57.39% | 110.37% | 91.04% | 80.01% | - | - |
| Research & Development | 9.92M | 5.32M | 5.06M | 2.17M | 3M | 7.02M | 11.27M | 12.77M | 15.61M | 18.33M |
| R&D % of Revenue | 28.64% | 11.82% | 11.11% | 0.19% | 30.94% | 118.98% | 154.41% | 170.32% | - | - |
| Other Operating Expenses | -2.68M | -7.91M | 735 | 154.77K | -5K | 0 | 0 | 0 | 0 | -396K |
| Operating Income | -24.96M | -15.92M | -8.55M | 2M | -8.28M | -13.6M | -17.85M | -19.08M | -22.6M | -41.77M |
| Operating Margin % | -72.04% | -35.36% | -18.78% | 0.18% | -85.37% | -230.44% | -244.58% | -254.41% | - | - |
| Operating Income Growth % | -0.87% | 0.36% | 0.46% | 1.23% | -5.13% | -0.64% | -0.31% | -0.07% | -0.18% | -0.85% |
| EBITDA | -13.42M | -15.76M | -8.41M | 2.16M | -7.91M | -13.17M | -17.46M | -18.7M | -22.25M | -41.7M |
| EBITDA Margin % | -38.72% | -34.99% | -18.46% | 0.19% | -81.52% | -223.25% | -239.21% | -249.33% | - | - |
| EBITDA Growth % | -0.01% | -0.17% | 0.47% | 1.26% | -4.66% | -0.67% | -0.33% | -0.07% | -0.19% | -0.87% |
| D&A (Non-Cash Add-back) | 11.54M | 166.75K | 142.51K | 154.77K | 374K | 424K | 392K | 381K | 343K | 69.33K |
| EBIT | -15.96M | -4.36M | -8.73M | 2.58M | -8.28M | -13.88M | -18.18M | -19.53M | -21.75M | -41.77M |
| Net Interest Income | 0 | 0 | 0 | 122K | 62K | -6K | -32K | -33K | 904K | 3.29M |
| Interest Income | 0 | 0 | 0 | 122K | 62K | 0 | 0 | 0 | 904K | 3.29M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 6K | 32K | 33K | 0 | 0 |
| Other Income/Expense | 6.46M | 11.55M | 179.24K | 606.03K | 7K | -286K | -354K | -481K | 847K | 3.85M |
| Pretax Income | -18.5M | -4.37M | -8.55M | 2.87M | -8.27M | -13.88M | -18.21M | -19.56M | -21.75M | -37.92M |
| Pretax Margin % | -53.4% | -9.71% | -18.77% | 0.25% | -85.3% | -235.29% | -249.42% | -260.83% | - | - |
| Income Tax | 0 | 0 | 1.47K | -864.22K | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 1% | 1% | 1% | 1% | 1% | 1% | 1% | 1% | 1% | 1% |
| Net Income | -18.5M | -4.37M | -8.55M | 2.87M | -8.27M | -13.88M | -18.21M | -19.56M | -21.75M | -37.92M |
| Net Margin % | -53.4% | -9.71% | -18.77% | 0.25% | -85.3% | -235.29% | -249.42% | -260.83% | - | - |
| Net Income Growth % | -1.1% | 0.76% | -0.96% | 1.34% | -3.89% | -0.68% | -0.31% | -0.07% | -0.11% | -0.74% |
| Net Income (Continuing) | -18.5M | -4.37M | -8.55M | 2.61M | -8.27M | -13.88M | -18.21M | -19.56M | -21.75M | -37.92M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -331.56 | -63.56 | -103.61 | 28.45 | -69.09 | -27.27 | -19.31 | -14.12 | -2.68 | -1.05 |
| EPS Growth % | -0.7% | 0.81% | -0.63% | 1.27% | -3.43% | 0.61% | 0.29% | 0.27% | 0.81% | 0.61% |
| EPS (Basic) | -331.56 | -63.56 | -103.61 | 28.45 | -69.09 | -27.27 | -19.31 | -14.12 | -2.68 | -1.05 |
| Diluted Shares Outstanding | 111.62K | 137.6K | 165.06K | 201.59K | 240.28K | 1.01M | 1.92M | 1.39M | 10.28M | 36.21M |
| Basic Shares Outstanding | 111.62K | 137.59K | 165.06K | 201.59K | 240.28K | 1.01M | 1.92M | 1.39M | 10.26M | 36.21M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
| Jun 2016 | Jun 2017 | Jun 2018 | Jun 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 14.48M | 17.03M | 15.35M | 18.73M | 10.81M | 20.61M | 4.82M | 3.73M | 51.67M | 98.52M |
| Cash & Short-Term Investments | 13.61M | 13.43M | 11.84M | 15.82M | 9.8M | 19.77M | 4.06M | 2.48M | 50.87M | 97.74M |
| Cash Only | 13.61M | 13.35M | 11.82M | 15.7M | 9.8M | 19.77M | 4.06M | 2.48M | 50.87M | 97.74M |
| Short-Term Investments | 0 | 76.84K | 22.04K | 126.76K | 1K | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 3.39M | 3.03M | 2.54M | 59K | 25K | 3K | 55K | 229K | 33K |
| Days Sales Outstanding | - | 2.74K | 2.43K | 81.79 | 222.01 | 154.66 | 15 | 267.67 | - | - |
| Inventory | 111.27K | -65.06K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | 391.26 | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 20.91K | 281K | 385.66K | 1K | 87K | 15K | 14K | 13K | 579K | 741K |
| Total Non-Current Assets | 377.87K | 387.3K | 326.16K | 478.33K | 935K | 771K | 1.15M | 735K | 536K | 1.07M |
| Property, Plant & Equipment | 377.87K | 341.96K | 234.33K | 469.23K | 769K | 577K | 993K | 613K | 449K | 991K |
| Fixed Asset Turnover | 0.92x | 1.32x | 1.94x | 24.12x | 0.13x | 0.10x | 0.07x | 0.12x | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 45.34K | 91.82K | 9.1K | 9K | 194K | 160K | 122K | 87K | 83K |
| Total Assets | 14.85M | 17.42M | 15.68M | 19.21M | 11.74M | 21.38M | 5.97M | 4.46M | 52.21M | 99.59M |
| Asset Turnover | 0.02x | 0.03x | 0.03x | 0.59x | 0.01x | 0.00x | 0.01x | 0.02x | - | - |
| Asset Growth % | -0.24% | 0.17% | -0.1% | 0.23% | -0.39% | 0.82% | -0.72% | -0.25% | 10.7% | 0.91% |
| Total Current Liabilities | 772.92K | 864.51K | 1.87M | 2.64M | 1.14M | 1.37M | 2.53M | 3.98M | 4.92M | 1.8M |
| Accounts Payable | 401.77K | 133.71K | 426.06K | 1.47M | 282K | 274K | 422K | 1.14M | 1.35M | 201K |
| Days Payables Outstanding | 1.41K | 233.49 | 469.4 | 1.26K | -556.38 | 813.09 | 17.11K | 1.09K | 1.44K | 185.27 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 192K | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 497K | 158.3K | 1.82M | 1.09M | 459K | 276K | 400K | 1.82M | 475K | 1.25M |
| Current Ratio | 18.73x | 19.70x | 8.20x | 7.10x | 9.51x | 15.05x | 1.90x | 0.94x | 10.49x | 54.67x |
| Quick Ratio | 18.58x | 19.77x | 8.20x | 7.10x | 9.51x | 15.05x | 1.90x | 0.94x | 10.49x | 54.67x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 13.44K | 26.89K | 35.26K | 0 | 370K | 0 | 559K | 284K | 38K | 495K |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 213K | 0 | 559K | 284K | 0 | 495K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 157K | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 13.44K | 26.89K | 35.26K | 0 | 0 | 0 | 0 | 0 | 38K | 0 |
| Total Liabilities | 786.36K | 891.4K | 1.91M | 2.64M | 1.51M | 1.37M | 3.09M | 4.26M | 4.96M | 2.3M |
| Total Debt | 0 | 0 | 0 | 0 | 405K | 213K | 811K | 559K | 284K | 849K |
| Net Debt | -13.61M | -13.35M | -11.82M | -15.7M | -9.4M | -19.56M | -3.25M | -1.92M | -50.58M | -96.89M |
| Debt / Equity | - | - | - | - | 0.04x | 0.01x | 0.28x | 2.77x | 0.01x | 0.01x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | -7.27x | - | - | - | - | - | - |
| Interest Coverage | - | - | - | - | - | -2266.00x | -557.94x | -578.21x | - | - |
| Total Equity | 14.07M | 16.53M | 13.77M | 16.57M | 10.24M | 20.01M | 2.88M | 202K | 47.25M | 97.3M |
| Equity Growth % | -0.23% | 0.17% | -0.17% | 0.2% | -0.38% | 0.95% | -0.86% | -0.93% | 232.9% | 1.06% |
| Book Value per Share | 126.03 | 120.11 | 83.42 | 82.20 | 42.61 | 19.80 | 1.50 | 0.15 | 4.60 | 2.69 |
| Total Shareholders' Equity | 14.07M | 16.53M | 13.77M | 16.57M | 10.24M | 20.01M | 2.88M | 202K | 47.25M | 97.3M |
| Common Stock | 110.26M | 119.56M | 120.54M | 114.92M | 1K | 1K | 0 | 0 | 1K | 2K |
| Retained Earnings | -98.1M | -104.32M | -107.86M | -98.93M | -116.64M | -130.12M | -148.33M | -167.89M | -190.26M | -228.18M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 1.92M | 1.29M | 1.1M | 581.98K | -1.95M | -1.46M | -1.25M | -830K | -892K | -839K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Jun 2016 | Jun 2017 | Jun 2018 | Jun 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -20.21M | -8.3M | -8.55M | 4.79M | -7.54M | -12.83M | -15.9M | -18.01M | -19.4M | -23.59M |
| Operating CF Margin % | -58.32% | -18.44% | -18.77% | 0.42% | -77.68% | -217.49% | -217.79% | -240.16% | - | - |
| Operating CF Growth % | -1.09% | 0.59% | -0.03% | 1.56% | -2.57% | -0.7% | -0.24% | -0.13% | -0.08% | -0.22% |
| Net Income | -18.5M | -4.37M | -8.55M | 2.61M | -8.27M | -13.88M | -18.21M | -19.56M | -21.75M | -37.92M |
| Depreciation & Amortization | 0 | 217K | 0 | 158K | 374K | 424K | 392K | 381K | 343K | 396K |
| Stock-Based Compensation | 0 | 386K | 0 | 957.2K | 237K | 634K | 870K | 452K | 830K | 17.43M |
| Deferred Taxes | 0 | -819.52K | 0 | -957.2K | 0 | 0 | 0 | -714K | 0 | 0 |
| Other Non-Cash Items | -1.7M | -4.47M | 0 | 700K | 2K | -16K | 10K | 717K | 1K | -764K |
| Working Capital Changes | 0 | 760K | 0 | 1.32M | 126K | 8K | 1.04M | 714K | 1.17M | -2.73M |
| Change in Receivables | 0 | 0 | 0 | 607K | 2.4M | 28K | 1K | -50K | -176K | 197K |
| Change in Inventory | 0 | 0 | 0 | 0 | -700K | -83K | -1.09M | -1.31M | 0 | 0 |
| Change in Payables | 0 | 0 | 0 | 740K | -1.7M | 55K | 1.09M | 1.36M | 0 | -2.38M |
| Cash from Investing | -255.4K | -232.07K | -107.98K | -399.19K | -94K | -221K | -13K | -1K | -179K | -18K |
| Capital Expenditures | -255.4K | -131.41K | -60.97K | -403.39K | -95K | -221K | -13K | -1K | -179K | -18K |
| CapEx % of Revenue | 0.74% | 0.29% | 0.13% | 0.04% | 0.98% | 3.75% | 0.18% | 0.01% | - | - |
| Acquisitions | - | - | - | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 30.33K | -47.01K | 202 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 17.51M | 6.1M | 6.25M | -688.12K | 1.77M | 22.52M | 0 | 16.02M | 68.03M | 70.48M |
| Debt Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - | - | - | - |
| Other Financing | 2.98M | 1.74M | -229.93K | -688.12K | -480K | -3.23M | 0 | -1.87M | -2.85M | 0 |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | -20.46M | -8.44M | -8.61M | 4.39M | -7.63M | -13.05M | -15.91M | -18.01M | -19.58M | -23.61M |
| FCF Margin % | -59.06% | -18.73% | -18.91% | 0.39% | -78.66% | -221.24% | -217.97% | -240.17% | - | - |
| FCF Growth % | -1.03% | 0.59% | -0.02% | 1.51% | -2.74% | -0.71% | -0.22% | -0.13% | -0.09% | -0.21% |
| FCF per Share | -183.34 | -61.31 | -52.17 | 21.76 | -31.75 | -12.92 | -8.28 | -13.00 | -1.91 | -0.65 |
| FCF Conversion (FCF/Net Income) | 1.09x | 1.90x | 1.00x | 1.67x | 0.91x | 0.92x | 0.87x | 0.92x | 0.89x | 0.62x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -114.29% | -28.58% | -56.45% | 18.9% | -61.73% | -91.79% | -159.08% | -1268.61% | -91.68% | -52.46% |
| Return on Invested Capital (ROIC) | -1820.26% | -658.42% | -250.17% | 106.24% | -723.56% | -1573.61% | -31507.06% | - | - | - |
| Gross Margin | 70.04% | 53.58% | 27.26% | 96.23% | 290.72% | -108.47% | 87.67% | -408% | - | - |
| Net Margin | -5340.09% | -970.99% | -1877.42% | 25.34% | -8529.9% | -23528.81% | -24942.47% | -26082.67% | - | - |
| Debt / Equity | - | - | - | - | 0.04x | 0.01x | 0.28x | 2.77x | 0.01x | 0.01x |
| Interest Coverage | - | - | - | - | - | -2266.00x | -557.94x | -578.21x | - | - |
| FCF Conversion | 1.09x | 1.90x | 1.00x | 1.67x | 0.91x | 0.92x | 0.87x | 0.92x | 0.89x | 0.62x |
| Revenue Growth | -58.21% | 29.96% | 1.14% | 2384.77% | -99.14% | -39.18% | 23.73% | 2.74% | -100% | - |
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|
| License | - | - | - | 59K | 73K | 75K |
| License Growth | - | - | - | - | 23.73% | 2.74% |
| Royalty | - | - | - | - | - | - |
| Royalty Growth | - | - | - | - | - | - |
| Service | - | - | - | - | - | - |
| Service Growth | - | - | - | - | - | - |
| Grant | - | - | 5K | - | - | - |
| Grant Growth | - | - | - | - | - | - |
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|
| AUSTRALIA | 378K | 14.63M | - | - | - | - |
| AUSTRALIA Growth | - | 3769.58% | - | - | - | - |
Benitec Biopharma Inc. (BNTC) reported $0.6M in revenue for fiscal year 2025. This represents a 2% increase from $0.5M in 2013.
Benitec Biopharma Inc. (BNTC) grew revenue by 0.0% over the past year. Growth has been modest.
Benitec Biopharma Inc. (BNTC) reported a net loss of $46.4M for fiscal year 2025.
Benitec Biopharma Inc. (BNTC) has a return on equity (ROE) of -52.5%. Negative ROE indicates the company is unprofitable.
Benitec Biopharma Inc. (BNTC) had negative free cash flow of $22.7M in fiscal year 2025, likely due to heavy capital investments.